Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Colorcon
Mallinckrodt
McKinsey
Merck

Last Updated: December 3, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TUKYSA

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Tukysa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03043313 ↗ Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Active, not recruiting Academic and Community Cancer Research United Phase 2 2017-06-23 This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.
NCT03043313 ↗ Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Active, not recruiting Cascadian Therapeutics Inc. Phase 2 2017-06-23 This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.
NCT03043313 ↗ Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Active, not recruiting National Cancer Institute (NCI) Phase 2 2017-06-23 This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.
NCT03043313 ↗ Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Active, not recruiting Seagen Inc. Phase 2 2017-06-23 This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.
NCT04430738 ↗ Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Recruiting Seagen Inc. Phase 1/Phase 2 2020-09-15 This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs. A side effect is anything the drug does other than treating cancer. It will also look at whether tucatinib works with these drugs to treat certain types of cancer. The participants in this trial have HER2-positive (HER2+) cancer in their gut, stomach, intestines, or gallbladder (gastrointestinal cancer).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tukysa

Condition Name

Condition Name for Tukysa
Intervention Trials
HER2-positive Breast Cancer 3
Breast Cancer 3
Colorectal Carcinoma 2
CNS Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tukysa
Intervention Trials
Breast Neoplasms 3
Colorectal Neoplasms 3
Neoplasm Metastasis 2
Adenocarcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tukysa

Trials by Country

Trials by Country for Tukysa
Location Trials
United States 35
Japan 8
France 1
Australia 1
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tukysa
Location Trials
California 3
Ohio 2
North Carolina 2
Illinois 2
District of Columbia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tukysa

Clinical Trial Phase

Clinical Trial Phase for Tukysa
Clinical Trial Phase Trials
Phase 2 3
Phase 1/Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tukysa
Clinical Trial Phase Trials
Recruiting 3
Not yet recruiting 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tukysa

Sponsor Name

Sponsor Name for Tukysa
Sponsor Trials
Seagen Inc. 3
Seattle Genetics, Inc. 2
Merck Sharp & Dohme Corp. 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tukysa
Sponsor Trials
Industry 9
Other 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Dow
McKinsey
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.